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Abstract—Our objective was to explore the relationship
between low vitamin D, secondary hyperparathyroidism, and
heterotopic ossification (HO) in patients with spinal cord injury
(SCI). Ninety-six subjects with acute or chronic motor complete
SCI participated. Levels of serum vitamin D25(OH), calcium,
and intact parathyroid hormone (PTH) were collected, and infor-
mation regarding nutritional patterns and fracture history was
obtained from subjects. Evidence of current or previous HO was
ascertained through chart review. Of the 96 subjects, 12 were
found to have developed HO, 11 with serum vitamin D25(OH)
between 5 and 17 ng/mL. Nine subjects exhibited secondary
hyperparathyroidism in the range of 72 to 169 pg/mL. Only one
subject demonstrated HO in the absence of low vitamin D. How-
ever, many subjects with low vitamin D (5–31 ng/mL) did not
have hyperparathyroidism or HO. Statistical testing demon-
strated a correlation between hyperparathyroidism and HO (p <
0.001) as well as hyperparathyroidism and vitamin D deficiency
(<20 ng/mL). Direct correlation between HO and low vitamin D
was not observed, but hyperparathyroidism may increase this
risk. We believe that those patients who demonstrate low vita-
min D and elevated PTH should be screened for HO in addition
to beginning vitamin supplementation. Initiating early treatment
of low vitamin D to restore therapeutic levels may prevent
development of HO.
Key words: bone, bone morphogenic protein, bone progenitor
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INTRODUCTION
The classical definition of heterotopic ossification
(HO), set forth by Hsu and Keenan [1], focuses on the
formation of lamellar bone in periarticular, nonossified
soft tissues [1–2]. However, HO in its mature form
reveals not only the presence of mature lamellar bone but
also cancellous bone, vessels, and bone marrow with evi-
dence of hematopoiesis [3–4]. New bone forms within
the muscle planes, rather than within the muscle itself,
and exists adjacent to the skeleton but exclusive of the
periosteum [2].
HO is characterized by muscle pain, decreased range
of motion (ROM), and inflammation in the affected
Abbreviations: ALK-P = alkaline phosphatase, BMD = bone
mineral density, BMP = bone morphogenic protein, CI = confi-
dence interval, EndMT = endothelial-mesenchymal transition,
FOP = fibrodysplasia ossificans progressive, HO = heterotopic
ossification, PTH = parathyroid hormone, ROM = range of
motion, SCI = spinal cord injury, T = thoracic.
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region and is associated with recent trauma and soft tis-
sue injury [1]. The reported incidence ranges from 10 to
53 percent depending on the study [5–6]. Some experts
have found that, in terms of patients with traumatic spinal
cord injury (SCI), HO is seen more often among those
with prolonged immobility, spasticity, deep vein throm-
boses, or pressure ulcers [7]. Because immobility from
prolonged hospitalization in an intensive care unit, venti-
lator dependence, and critical illness can all place a
patient at risk for any of these conditions, a direct influ-
ence of pressure ulcers, spasticity, or venous thromboem-
bolism on development of HO has been challenged [8].
Subbarao and Garrison noted that pressure ulcers and
increased spasticity may be associated with HO yet are
not considered to be causative factors [9]. However, com-
pleteness of SCI, the traumatic nature of neurological
injury, and direct muscle trauma do appear to be stronger
influencing factors in HO development [1,7].
Although inflammation, completeness of injury, and
immobility following injury may predispose the patient
to heterotopic bone formation, the full scope of the con-
dition is not observed until 1 to 4 mo after initial injury
[3,8]. The onset of posttraumatic HO in the setting of
acute SCI is one of several adverse sequelae seen in the
subsequent months following the initial injury. Unlike
other secondary adverse complications of traumatic SCI,
such as pressure ulcers, venous thromboembolism, spas-
ticity, and autonomic dysreflexia, HO has few measures
of effective intervention. Treatment rarely results in com-
plete resolution of the disorder.
In part, the challenge of prevention is related to the
imprecise etiology of the condition and the various types
of heterotopic bone. Subbarao and Garrison have proposed
four different types of soft tissue ossification: (1) ossifica-
tion due to neurologic disorders such as SCI and brain
injury, (2) traumatic myositis ossificans due to blunt injury
or direct contusion to the area, (3) idiopathic HO due to
burns or other medical causes, and (4) congenital fibrodys-
plasia ossificans progressive (FOP) [9]. Whether the same
or different mechanisms of formation exist among the dif-
ferent forms of HO is unknown.
Our group has recently completed an observational
study of vitamin D levels in 42 subjects with acute SCI,
defined as 2 to 6 mo postinjury, and 54 subjects with
chronic SCI, defined as >1 yr postinjury [10]. A high per-
centage of subjects with deficient levels of vitamin D
exhibited HO in bones below the neurological level of
injury. Some had severe deficiency (<13 ng/mL) of vita-
min D with the presence of secondary hyperparathyroid-
ism. This group of subjects serves as the sample of study
in our report. A number of our subjects with chronic SCI
reported having a large bone growth on their hip or knee
several months after SCI but never sought evaluation,
attributing it to inactivity or discontinuing their therapy.
Many did not learn its diagnosis by the name of HO until
their annual SCI visit.
The purpose of our investigation was to examine any
possible relationship between vitamin D deficiency, sec-
ondary hyperparathyroidism, and HO formation. Our
specific aims were—
1. To determine whether HO is more common in persons
with hyperparathyroidism and vitamin D deficiency.
2. To determine what minimum serum value of vitamin D
is necessary to reduce risk of HO.
METHODS
Our study was a subproject of a case series examin-
ing subjects with acute (2–6 mo postinjury) and chronic
(>1 yr postinjury) SCI for possible vitamin D deficiency.
Table 1 shows inclusion and exclusion criteria [11]. All
subjects were cervical level 3 to thoracic (T) level 10,
American Spinal Injury Association Impairment Scale
grades A or B, and between ages 19 and 55. The age
range was derived from another study examining vitamin
D levels with focus on the young and middle-aged popu-
lation. Injuries caudal to T10 were eliminated to prevent
possible inclusion of subjects with conus medullaris or
cauda equina injuries. Both sexes and all racial groups
were invited to participate.
Each subject completed a questionnaire that requested
information about the following: any premorbid diagnosis
of osteoporosis; history of other fractures unrelated to the
original trauma; history of renal or liver failure or other
liver disease (cirrhosis, hepatitis); medication use, includ-
ing any seizure medications known to cause osteoporosis
or to impair vitamin D absorption; family history of osteo-
porosis; and family or personal history of lactose intoler-
ance. Charts were also screened for documentation of
these conditions. Subjects who consumed more than
400 IU/d of vitamin D as well as those who were pre-
scribed bisphosphonates were not eligible. These criteria
were applied to both subjects with acute and chronic SCI.
Values of serum vitamin D25(OH) and intact para-
thyroid hormone (PTH) were collected in each subject.1179
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The form of vitamin D chosen for study was serum
D25(OH) since it is the major circulating vitamin D
metabolite and best reflects the overall nutritional status
of the subject, determined by solar and dietary sources
[12]. As part of standard of care, subjects with low vita-
min D levels, regardless of status of PTH values, were
recommended for treatment. Some chose to pursue treat-
ment at our clinic, while others chose to follow up with
their primary care physician. In cases with severe hyper-
parathyroidism, subjects were referred to an endocrinolo-
gist for more intense treatment than could be provided at
our center. For subjects with data available, results for
follow-up are given.
Inpatient and/or outpatient charts of each subject
were reviewed for reports of any diagnostic studies
revealing the presence of HO or documentation of its
presence in clinic notes. No additional images to screen
for HO were performed for the purposes of this study.
Subjects were also interviewed when data obtained from
chart review were unclear. If during the interview a sub-
ject reported decreased ROM in a unilateral hip or knee,
additional images may have been obtained as part of
standard of care. Subjects were asked about known pres-
ence of heterotopic bone and whether they had been seen
for this condition in other hospitals or clinics. No screen-
ing for HO was performed in the absence of notable clini-
cal examination findings or apart from a subject’s self-
reported joint pain, stiffness, and decreased ROM.
RESULTS
Of the 96 subjects who participated in our previous
study [10] on the presence of vitamin D deficiency, 12
reported HO as verified by review of the medical record,
including imaging studies either at the institution of care or
at an outside hospital. Of the 78 subjects with low vitamin D
(<32 ng/mL), 11 demonstrated HO formation. One patient
with a normal vitamin D value of 52 ng/mL also had HO. Of
the 12 subjects with HO, 9 exhibited marked hyperparathy-
roidism (PTH range: 71–169 pg/mL). The nine subjects
with elevated PTH all had serum vitamin D levels that were
deficient (<20 ng/mL). Among the subjects with low vita-
min D, those with HO had serum vitamin D25(OH) levels
of 5 to 17 ng/mL, while those without HO ranged from 5 to
31 ng/mL. There were 27 subjects with low serum D25(OH)
levels between 20 and 31 ng/mL, but no subjects in this
range had HO.
In all subjects with HO, the location of bone forma-
tion was below the neurological level of injury. The most
common location was the hip, followed by the knee. In
two subjects, multiple joints were affected. Each subject
with HO indicated that onset of clinical symptoms
occurred after being discharged from acute inpatient
rehabilitation, a duration that ranged from 30 to 65 d.
Chart review indicated that the onset of HO occurred
between 6 and 12 mo postinjury for five patients and over
the first 3 yr for the others, with the exact date of onset
unknown. The twelfth patient, a 48 yr old male with hip
Table 1.
Criteria for participation (adapted from Oleson et al. [10]).
Criteria Inclusion Exclusion
Age (yr) 19–55. Outside age range.
AIS C3*–T10 (grade A or B). Motor incomplete SCI (grade C or D) or neurologic level 
below T10.
Vitamin D Use of multivitamin with 400 IU cholecalciferol 
permissible (was given to all acute participants not 
eating well).
Use of high-potency vitamin D supplements on regular 
basis prior to initial assessment. Use of various medications 
that deplete vitamin D stores, or total intake from daily sup-
plements exceeds 400 IU vitamin D.
Medical History — Previous diagnoses of childhood rickets or history of other 
adult metabolic bone disorder, including osteoporosis.
Communication Ability to understand consent process and agree to 
participation. (Witnesses/assistants offered to those 
unable to give signature). Must be able to provide 
answers to questionnaire for patient history.
Unable to understand English (consent not available in 
multiple languages). Severe cognitive impairment limit-
ing ability to give informed consent. Other condition pre-
cluding consent process or questionnaire completion.
*May be on ventilator as long as still able to communicate to give informed consent.
AIS = American Spinal Injury Association Impairment Scale, C = cervical, SCI = spinal cord injury, T = thoracic.1180
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HO, had normal levels of vitamin D at postinjury years 1
and 2 (46 and 52 ng/mL, respectively), with normal PTH
and calcium levels at the time of interview. His onset
appeared 2 yr postinjury. Two months after HO was
found, the subject experienced a series of hospitalizations
for weakness and fever and was diagnosed with a paraneo-
plastic syndrome. This was the only subject of the 96 in
the study who demonstrated HO in the absence of low
vitamin D (<32 ng/mL).
Two subjects among the 78 with low vitamin D (5
and 10 ng/mL, respectively) but with presence of HO
failed to reach the level of laboratory-defined hyperpara-
thyroidism of >65 ng/mL. Their PTH values were 40 and
56, respectively. If left untreated for low vitamin D for
additional time, those two subjects may well have dem-
onstrated secondary hyperparathyroidism. Both were in
the second year of their SCI. Of the 18 subjects with nor-
mal vitamin D levels (32 ng/mL), all had therapeutic
PTH values and only 1 subject had HO.
Table 2 summarizes the differences found in PTH
levels and HO incidence among those with and without
low vitamin D (serum D25(OH) levels of <32 ng/mL).
Results indicate that presence of HO was correlated with
elevated PTH. Vitamin D served as the stratification vari-
able using a threshold of 32 ng/mL, since this represents
the lower limit of the normal range (32–100 ng/mL). The
calculation was performed using a one-sided Cochran-
Mantel-Haenszel test, with odds ratio of infinity (95%
confidence interval [CI]: 43.260–infinity, p < 0.001).
However, presence of HO did not correlate specifically
with a vitamin D level below 32 ng/mL by a two-sided
Cochran-Mantel-Haenszel test, with odds ratio 1.953
(95% CI: 0.032–39.608, p = 0.51). Although we did
observe an inverse relationship between vitamin D levels
and PTH values, the correlation was not significant using
32 ng/mL as the division between abnormal and normal
vitamin D values (p = 0.20).
Table 3 illustrates our findings for levels of vitamin D
below 20 ng/mL. Similarly, the presence of HO was cor-
related with elevated PTH using the lower threshold of
serum vitamin D25(OH) of 20 ng/mL as the stratification
variable. This relationship was determined by a one-sided
Cochran-Mantel-Haenszel test, with estimated odds ratio
of infinity (95% CI: 28.193–infinity, p < 0.001). Presence
of HO did not directly correlate with a vitamin D level
below 20 ng/mL either, when calculated by a two-sided
Cochran-Mantel-Haenszel test, with odds ratio 0.554
(95% CI: 0.009–11.015, p > 0.99). However, correlation
does exist between vitamin D level <20 ng/mL and ele-
vated PTH. The latter finding was determined by a two-
sided Fisher Exact test, with estimated odds ratio of 0.000
(95% CI: 0.000–0.476, p = 0.01).
Our results suggest that the risk of developing ele-
vated PTH appears to have an onset between serum
D25(OH) levels of 20 and 32 ng/mL. While values above
20 ng/mL but below 32 ng/mL may cause mild increases
in PTH, their inclusion may present a confounder when
differentiating subjects with clearly therapeutic levels
(32 ng/mL) from those with clearly insufficient values
(<20 ng/mL). In the best interest of patient care, giving
persons with SCI vitamin D to maintain a minimum level
of 32 ng/mL may avoid onset of hyperparathyroidism
that can lead to HO.
FOLLOW-UP TO SUGGESTED TREATMENT 
FOR SUBJECTS WITH VITAMIN D DEFICIENCY
Available 1 yr follow-up data exists for five of nine
subjects with low vitamin D, laboratory-defined hyper-
parathyroidism, and presence of HO. Subject 6 had a 9 mo
follow-up visit, but the study concluded prior to his 1 yr
follow-up. Subjects were treated with 1,000 IU of chole-
calciferol twice daily (oral vitamin D3). All subjects
admitted to partial degrees of noncompliance with medi-
cation but felt that they took the pills at least 5 of 7 d of
Table 2.
Cross-tabulation of parathyroid hormone (PTH) and heterotopic
ossification (HO) incidence using low vitamin D threshold (serum
D25(OH) level: 32 ng/mL).
PTH
Level
Serum D25(OH)
<32 ng/mL
Serum D25(OH)
32 ng/mL
HO No HO Yes HO No HO Yes
Normal 67 2 17 1
Elevated 0 9 0 0
Table 3.
Cross-tabulation of parathyroid hormone (PTH) and heterotopic
ossification (HO) incidence using low vitamin D threshold (serum
D25(OH) level: 20 ng/mL).
PTH
Level
Serum D25(OH)
<20 ng/mL
Serum D25(OH)
20 ng/mL
HO No HO Yes HO No HO Yes
Normal 44 2 40 1
Elevated 0 9 0 01181
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the week (72% compliant). Although each subject was
offered nonsteroidal anti-inflammatory medications for
discomfort, with appropriate gastrointestinal protection,
most found this medication unsuccessful at treating dis-
comfort from the HO, and compliance was well under
50 percent.
During the follow-up period, no subjects had addi-
tional HO formation after initiation of treatment with
vitamin D, with or without etidronate. The latter had been
prescribed only for those with HO who had not reached
maturity. Within 3 mo of starting vitamin D treatment,
the six subjects who presented for follow up had x-ray
reports indicating that maturity of HO had been reached.
Their triple-phase bone scans were no longer active, and
PTH values had returned to the normal range in all but
one subject, whose level was 71 ng/mL. Each subject had
serum D25(OH) levels higher than at baseline but under
the lower limit of normal (32 ng/mL).
DISCUSSION
In addressing the specific aims established at the outset
of our study, we found that HO does appear to be more
common in persons with hyperparathyroidism, but we were
unable to support a direct correlation of HO with vitamin D
levels. However, vitamin D25(OH) levels <20 ng/mL were
significantly (negatively) correlated with hyperparathyroid-
ism. While it is unknown what precise value of vitamin D
may place an individual at risk of developing HO (through
its correlation with hyperparathyroidism), we advise main-
taining a serum vitamin D25(OH) level 32 ng/mL. Only
one subject with therapeutic vitamin D levels demonstrated
HO, and his condition may have been attributed to a para-
neoplastic syndrome.
We had 23 subjects with vitamin D levels between 20
and 31 ng/mL. It could be that subjects with milder
degrees of low vitamin D were identified early enough to
prevent secondary hyperparathyroidism. An alternative
explanation is that hyperparathyroidism is a secondary
consequence of low vitamin D, and in our investigation,
was seen only among chronic patients. Because only a
limited number of subjects had vitamin D levels between
20 and 32 ng/mL, small sample size may contribute to
lack of significant findings in this range.
Rationale for Treatment of Low Vitamin D Levels
Given the large number of medications already taken
by those with SCI, both inpatient and outpatient, some
may question the need to treat mild amounts of vitamin D
deficiency. Garland et al. found that 24 percent of bone
mineral density (BMD) in the distal femur of subjects
with complete SCI is lost within 4 mo of SCI and 35 per-
cent of BMD is lost within 16 mo [13]. While this early
phase of SCI contains the period of greatest loss, Bauman
and Spungen and Bauman et al. demonstrated continued
BMD loss at a slower rate in the years following acute
SCI [14–15]. The actual incidence of pathologic fractures
in the population with SCI is approximately 6 percent,
but this figure represents those with complete as well as
incomplete SCI, where partial movement is preserved
[16]. Those with complete SCI (no motor or sensory
function below the injury level [17]) are estimated to
have a 10-fold greater fracture rate than subjects with
incomplete SCI [16]. Given the potential contribution to
continued osteoporosis following SCI, we advocate sup-
plementation with vitamin D2 or D3 up to the reference
range of 32 to 80 ng/mL.
The Endocrine Society guidelines recommend an
intake of at least 600 to 800 IU oral vitamin D3 for adults
in the therapeutic range but advise considerably higher
doses of 50,000 units of ergocalciferol (vitamin D2)
weekly for 8 wk if subjects are deficient [18]. Concerns
have arisen that persons with SCI who receive vitamin D
supplementation are at increased risk of kidney stones.
Immobilization immediately following acute SCI does
cause hypercalcemia and hypercalciuria [14], but no
study has shown that supplementation with vitamin D in
SCI increases this occurrence. In addition, several recent
investigations of patients with a tendency for nephrolithi-
asis, who were treated for coexistent vitamin D defi-
ciency, failed to show a relationship between new stone
formation and vitamin D supplementation [19–21]. Eis-
ner et al. examined 169 patients with variable levels of
serum D25(OH) and found that urinary excretion of cal-
cium was not statistically different among those with
vitamin D deficiency (<20 ng/mL), those with vitamin D
insufficiency (20–29 ng/mL), and those with serum
D25(OH) levels 30 ng/mL [19].
Tang et al. studied 16,286 participants in the National
Health and Nutrition Examination Survey [20]. Findings
indicated that serum vitamin D25(OH) levels were not
significantly different in stone and nonstone formers, and
more specifically, that higher amounts of serum vitamin1182
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D25(OH) in the 40 to 50 ng/mL range were not associated
with increased stone formation. While Leaf et al. did find
higher urinary excretion of calcium in 11 subjects among
a small sample of 29 known stone formers, no hypercalce-
mia was observed and no adverse sequelae arose from the
increased urinary calcium [21]. They advocated that such
patients be treated for vitamin D deficiency but recom-
mended additional monitoring of 24 h urinary calcium
excretion following supplementation.
In looking at the calcium levels of subjects in our study,
all were within the reference range of 8.5 to 10.5 mEq/dL set
by our clinical laboratory [10]. It appears that the role of
PTH and its interactions with proteins expressed in the post-
traumatic setting, such as bone morphogenic protein (BMP),
contribute more to the development of HO than do calcium
levels alone. However, up to now, the mechanism of how
HO forms at the cellular level has largely been speculative.
Low Vitamin D Levels in African Americans
Although normal vitamin D levels have traditionally
been defined as 32 ng/mL [22–23], Wright et al. recently
proposed that a lower minimum vitamin D value of
20 ng/mL may be adequate in African Americans [24].
Their conclusions are based on examination of large studies
of African-American subjects with osteoarthritis. In these
reports, PTH levels did not demonstrate upregulation
unless serum vitamin D25(OH) levels were <20 ng/mL,
suggesting that perhaps therapeutic values for this group
have a lower limit of 20 ng/mL (range: 20–100 ng/mL)
instead of 32 ng/mL (range: 32–100 ng/mL). Since hyper-
parathyroidism develops as a secondary effect to low vita-
min D, it is appropriate to look at our chronic subjects in
terms of our previous work [10]. However, we are unable to
give clinical data to support the lack of complications in
this borderline range of serum vitamin D in African Ameri-
cans with chronic SCI, simply because 92.3 percent of sub-
jects had levels less than 20 ng/mL, with just one subject
between 20 and 31 ng/mL and one subject with 32 mg/
mL. Based on uncertainty of the lower limit of normal and
a window of normal values extending far above that, we
encourage treatment of low vitamin D for persons of all
ethnicities up to the value of 32 ng/mL, provided that an
affected individual is able to tolerate oral supplementation.
Moreover, we believe that maintaining vitamin D
levels in the normal range of 32 ng/mL is most desirable
not only for HO prevention but also for many secondary
health benefits as described in our previous work [10].
The current findings also suggest that keeping PTH
within the normal range may prevent HO formation in
the population with SCI. Because low vitamin D levels
can develop within weeks of initial SCI, monitoring both
vitamin D25(OH) levels and PTH levels is highly recom-
mended in the weeks and months following initial SCI.
In addition, annual surveillance of serum vitamin D val-
ues is also recommended since low vitamin D is even
more common in the setting of chronic SCI.
Proposed Mechanisms of Heterotopic Ossification 
Formation
Chalmers et al. has suggested that three general con-
ditions are needed for the formation of heterotopic bone:
(1) the presence of osteogenic precursor cells, now
believed to be primitive mesenchymal cells; (2) an induc-
ing agent or stimulus that has been identified as BMP
(BMP-2 vs BMP-4); and (3) a permissive environment
friendly to osteogenesis [11]. The role of BMP was
explored by Urist, who found that demineralized bone
matrix can evoke bone formation ectopically when sup-
plied with BMP [25]. BMP is released from healthy bone
tissue in the settings of immobilization, trauma, venous
stasis, and inflammation. These conditions are consis-
tently observed in the early weeks following traumatic
SCI [1]. Through the actions of BMP, mesenchymal cells
in muscle are altered and transformed into osteoblasts,
which then develop into mature bone cells.
Stover has affirmed that HO begins forming in the intra-
muscular connective tissue, first through an initial deposi-
tion of calcium phosphate, which later ossifies through
deposition of hydroxyapatite crystals [26]. The hip is the
most common joint affected, followed by the knee [26–27].
Elbow and shoulder joints are less commonly affected, as
are smaller joints of the hand [28]. With rare exception,
heterotopic bone is found below the neurological level of
injury [26]. In traumatic SCI, as well as other traumatic
conditions, the two primary factors that appear responsi-
ble for the etiology of bone deposition at a cellular and
molecular level appear to be the presence of BMPs [29–
32] and the ischemic degeneration of involved muscle
[33–34]. The sources of BMPs in muscle are mesenchy-
mal cells and endothelial cells; the target cells in the mus-
cle that BMPs act upon are mesenchymal stem cells and
smooth muscle cells [35].
In a series of cell line experiments, Benayahu et al.
observed that when BMP was added to mesenchymal
stromal cells that were multipotent in nature (capable of
differentiating into osteoblasts, fibroblasts, adipocytes, or1183
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other mesenchymal cells), alkaline phosphatase (ALK-P)
activity increased by as much as 10-fold [36]. These pre-
mature, mesencymal stem cells from bone marrow
stroma have an inherent potential for proliferation and
are considered preosteoblastic. In contrast, when BMP
was added to a mature osteoblastic cell line, ALK-P
activity increased by up to fivefold. We found that ALK-
P activity was increased in both forms of BMP tested,
BMP-2 and BMP-3, with BMP-2 generally exhibiting
more expression.
The same series of experiments was repeated with the
addition of PTH to each of the mesenchymal stromal lines
[36]. The premature osteoblastic cell line was noted to
have three times greater ALK-P activity after PTH was
added. However, PTH did not further increase the ALK-P
activity in the mature osteoblastic cell line. Finally, when
premature cells supplied with PTH were then challenged
with BMP-2, there was a 12-fold increase in ALK-P
activity. These findings suggest that hyperparathyroidism
and potentially even high normal levels of PTH may the
increase the risk of HO in settings of increased BMP, such
as trauma and immobilization [36]. Apart from trauma, an
essential anabolic action of PTH is the enhancement of
osteoblastic activity [37], which may further increase the
risk of HO.
One group has recently offered a new theory that
could lead to novel treatments for the condition of HO.
Medici and Olsen have proposed a mechanism of endo-
thelial-mesenchymal transition (EndMT) [38], described
as a form of dedifferentiation of endothelial cells to a stem
cell phenotype. This complex can subsequently form one
of three types of cells: bone, cartilage, or fat. Various pro-
moters or inhibitors that influence this primitive stem cell
or a downstream intermediate may direct the ultimate fate
of the cell to its destination type. Based on their analysis,
Medici and Olsen propose that vascular endothelial cells
are the leading candidate for the cellular origin of HO and
its presence in FOP. In this disorder, 50 percent of bone
lesions arise from an endothelial origin, but the source of
the remaining lesions is unknown. Animal experiments
have recently failed to show a significant contribution
from vascular smooth muscle cells [39–40]. It is unclear
whether a similar mechanism involving cells of endothe-
lial origin applies in patients with SCI. The idea that
human origins of HO may be different from those
observed in previously established animal models offers
new insights on treatment for a condition that has largely
been resistant to pharmacologic intervention.
Other than prescribing etidronate to prevent further
mineralization in established cases of HO [6,35,41–42]
and using nonsteroidal anti-inflammatory agents that are
contraindicated in the immediate postoperative period of
spine fracture stabilization, few interventions have been
attempted. Except in cases of early identification and treat-
ment, limited gains have been achieved from these noted
measures. This leaves patients with the option of pursuing
surgical resection of the area of HO involved once it
matures, raising a number of concerns in patients who may
have already undergone many procedures for their original
injury. Surgery carries complications of blood loss, super-
ficial or deep wound infection, osteomyelitis, further neu-
rologic or vascular injury, and recurrence of HO [27,43–
46]. Medici and Olsen report that vascular endothelial
growth factor, as well as several EndMT-inducing tran-
scription factors, may serve as potential inhibitors of HO
formation and therefore offer another avenue of potential
treatment for patients affected by HO [39].
CONCLUSIONS
HO appears to be more common in persons with ele-
vated PTH. If vitamin D levels in patients with SCI are
found to be low, supplementation to achieve a goal of
serum vitamin D25(OH) 32 ng/mL should be recom-
mended. PTH levels should be checked with initial and
subsequent vitamin D testing and closely monitored
through the first year after SCI. Maintaining therapeutic
serum vitamin D levels will reduce the likelihood of
developing HO by creating a less permissive environ-
ment for its formation. Findings in the literature suggest
that BMP-2, combined with PTH in the setting of prema-
ture osteoblasts, can increase ALK-P activity. This
upregulation may contribute to the occurrence of HO in
persons with additional risk factors, including immobil-
ity, inflammation, and hyperparathyroidism, all commonly
observed in those with traumatic SCI.
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